scispace - formally typeset
N

Nebojsa Arsenijevic

Researcher at University of Kragujevac

Publications -  223
Citations -  7439

Nebojsa Arsenijevic is an academic researcher from University of Kragujevac. The author has contributed to research in topics: Immune system & Mesenchymal stem cell. The author has an hindex of 39, co-authored 204 publications receiving 5477 citations. Previous affiliations of Nebojsa Arsenijevic include Lund University & University of California, Davis.

Papers
More filters
Journal ArticleDOI

Ethical and Safety Issues of Stem Cell-Based Therapy.

TL;DR: An overview of the most important ethical issues in stem cell therapy is provided, as a contribution to the controversial debate about their clinical usage in regenerative and transplantation medicine.
Journal ArticleDOI

Analysis of cycloheximide-induced apoptosis in human leukocytes: Fluorescence microscopy using annexin V/propidium iodide versus acridin orange/ethidium bromide

TL;DR: Apoptosis is a highly regulated and programmed cell breakdown process characterized by numerous changes and is implicated in many pathological as well as physiological processes, it is vital to have reliable methods for detecting cell death.
Journal ArticleDOI

Mesenchymal Stem Cell-Derived Exosomes and Other Extracellular Vesicles as New Remedies in the Therapy of Inflammatory Diseases.

TL;DR: Results obtained revealed that both local and systemic administration of MSC-EVs efficiently suppressed detrimental immune response in inflamed tissues and promoted survival and regeneration of injured parenchymal cells.
Journal ArticleDOI

Molecular Mechanisms Responsible for Therapeutic Potential of Mesenchymal Stem Cell-Derived Secretome

TL;DR: Therapeutic effects of MSC-sourced secretomes relied on their capacity to deliver genetic material, growth and immunomodulatory factors to the target cells enabling activation of anti-apoptotic and pro-survival pathways that resulted in tissue repair and regeneration.
Journal ArticleDOI

Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells

TL;DR: A previously unrecognized role for IL‐33 is shown in promoting breast cancer progression through increased intratumoral accumulation of immunosuppressive cells and by diminishing innate antitumor immunity.